Blog
RSS FeedPosted by Michael Wonder on 20 Jun 2022
Zeposia is included in the high-cost protection with limitation
17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022. ...
Posted by Michael Wonder on 20 Jun 2022
Givlaari is included in the high-cost protection with limitation
17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...
Posted by Michael Wonder on 16 Jun 2022
Subsidy for medicine for Duchenne muscular dystrophy expires
16 June 2022 - The TLV has decided that Translarna, which is subsidised for patients with Duchenne muscular dystrophy, will not ...
Posted by Michael Wonder on 08 Jun 2022
TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios
8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...
Posted by Michael Wonder on 02 Jun 2022
TLV reconsiders subsidy of the IL-17 and IL-23 inhibitors
2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...
Posted by Michael Wonder on 25 May 2022
Health economic assessment of Trodelvy in advanced triple negative breast cancer
23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan). ...
Posted by Michael Wonder on 18 May 2022
TLV reconsiders subsidy of CGRP inhibitors
18 May 2022 - TLV has started a review of the CGRP inhibitors. ...
Posted by Michael Wonder on 17 May 2022
Health economic assessment of Xevudy for the treatment of COVID-19
17 May 2022 - TLV has produced a health economic assessment for the regions for the drug Xevudy (sotrovimab). ...
Posted by Michael Wonder on 16 May 2022
Tepmetko is granted a temporary subsidy
16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Abecma in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel). ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Blenrep in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin). ...
Posted by Michael Wonder on 04 May 2022
New handbook on health economic assessments of medical devices
4 May 2022 - TLV performs health economic assessments of medical technology products at the request of the Medical Technology Product ...
Posted by Michael Wonder on 02 May 2022
TLV submits proposals for increased access to new gene therapies
2 May 2022 - How should society handle new gene therapies for serious diseases, where the effect of the drugs is ...
Posted by Michael Wonder on 26 Apr 2022
Health economic assessment of Leqvio in the treatment of high LDL cholesterol and mixed lipid disorders
26 April 2022 - The Swedish Dental and Pharmaceutical Benefits Agency has undertaken a health economic assessment of Leqvio (inclisiran) for ...
Posted by Michael Wonder on 19 Mar 2022
Final reconciliation of savings from side agreements for the full year 2021
18 March 2022 - TLV has presented the final reconciliation to the government of the outcome of the rebates in ...